Larimar Therapeutics (LRMR.O): Quick Thoughts Ahead of Monday’s Regulatory and Clinical Update; Reiterate Buy/High Risk

Research evidence excerpt

Larimar Therapeutics (LRMR.O): Quick Thoughts Ahead of Monday’s Regulatory and Clinical Update; Reiterate Buy/High Risk

Action |

26 Jun 2026 17:06:53 ET │ 11 pages

Larimar Therapeutics (LRMR.O)

Quick Thoughts Ahead of Monday’s Regulatory and Clinical Update;

Reiterate Buy/High Risk

CITI’S TAKE Buy / High Risk

Larimar will host an investor call on Monday, June 29th (webcast here) to Price (26 Jun 26 16:00) US$3.66

discuss a regulatory update and topline open-label study data for Target price US$14.00

nomlabofusp in Friedreich’s ataxia. The timing falls in line with Larimar’s

Expected share price return 282.5% guidance of initiating a rolling BLA and disclosing clinical data included in

the filing by June 2026. We continue to believe that the previously Expected dividend yield 0.0%

disclosed skin frataxin data suggest nomlabofusp is driving a non- Expected total return 282.5%

symptomatic, carrier-like phenotype. In Monday’s update, we anticipate Market Cap US$380M

the disclosure will build upon previous data cuts with a greater N,

including more patients with one year of treatment. We’ll be looking for

consistent positive trends across multiple outcomes measures (mFARS,

9HPT, etc), particularly in comparison to an FDA-aligned-upon reference Samantha Semenkow, Ph.D.AC

group from the FACOMS natural history study, and a safety profile in-line +1-716-730-7388

with prior disclosures. Collectively, we believe a data package checking samantha.semenkow@citi.com

these boxes supports the potential for accelerated approval with Benjamin E. Paluch,Ph.D.

favorable risk/reward. +1-716-730-8388

benjamin.paluch@citi.com

Model Update — We are updating our LRMR model with 1Q26 actuals. We have made

OpEx and balance sheet adjustments. Net, these changes impact our EPS estimates